Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?

2026-03-07 07:34:22

Abstract generation in progress

Is Novo Nordisk (NVO 1.25%) a bargain or a value trap as it battles Eli Lilly (LLY +0.72%) for GLP‑1 leadership, execution credibility, and premium growth? Watch the video below to see how investors might navigate this high‑stakes rivalry.

*This video was published on Feb. 24, 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.